Filed pursuant to Rule 425 under the Securities Act of 1933 and
deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934
Filer: Kindred Healthcare, Inc.
(Commission File No. 001-14057)
Subject Company: Gentiva Health Services, Inc.
(Commission File No. 001-15669)
Kindred Healthcare gentiva
&
Reach Definitive Agreement Creating Nation-Wide Integrated Care Delivery System Preferred by Consumers and Payors
October 9, 2014
Combination Will Help Transform the American Healthcare Delivery System by
Providing Patient-Centered, Coordinated Care at Home and Across the Continuum of Care
The combination of Kindred and Gentiva will further enhance Kindreds
industry leading position as the Nations premier post-acute and rehabilitation services provider and make Kindred at Home the largest and most geographically diversified Home Health and Hospice organization in the United States.
The Combined Company Will:
Serve more than one million patients per year
Operate in 47 states in over 2,800 locations
Employ more than
109,000 teammates
Making it the 4th largest healthcare employer in the U.S.
Overlap in 20 of 23 current and targeted Kindred Integrated Care Markets
Strategic Benefits of the Combination
Continue The
Care: As the U.S. population ages, demand for patient-centered healthcare is growing rapidly and Kindred is pioneering an integrated approach to address this demand implementing a better model to improve clinical outcomes and patient
safety, smooth care transitions and lower costs.
Kindreds Continue The Care strategy delivers the services that patients need across the full
spectrum of care, from transitional inpatient hospitalization, to post-acute rehab and skilled nursing services, to home health and hospice care.
Care Managers to
Smooth Transitions
Physician Information Coverage Across Sharing and IT
Sites
of Care Connectivity
PATIENT-CENTERED CARE MANAGEMENT
Mechanisms APPROACH
Condition- to Make Patient Specific Clinical Programs, Care Placement Pathways and Outcome
Decisions Measures
Transitional Personal Care Hospitals Home Care Assistance Inpatient Hospice Rehabilitation Home Higher Subacute Health Lower Units Outpatient Care Nursing and Rehabilitation
Rehabilitation Assisted Centers Living
Patient Acuity
The merger of Kindred
and Gentiva accelerates the development of this integrated approach to patient care, creating significant value for both companies patients, employees and shareholders.
Kindred with Gentiva Creates Multiple Platforms for Care Coordination and Growth
Building on Kindreds industry leadership, the combined company will advance Kindreds leadership in integrated post-acute care, including long-term acute care,
rehabilitation, skilled nursing, home health and hospice care.
*Kindred Hospitals Kindred at Home Rehabcare Kindred Nursing and rehabilitation
#1 Operator of Transitional Care Hospitals(1)
$2.5 billion Revenues(3)
97 Transitional Care Hospitals(4)
7,145 licensed beds(4)
5 Inpatient Rehabilitation Hospitals with 215 licensed beds(4)
#1 Operator of Home Health and
Hospice(1)
$2.2 billion Pro Forma Revenues(5)
697 sites of service in 41
states
151 in Kindreds Integrated Care Markets
44,500 caregivers
serving 126,100 patients on a daily basis
*Combined with Gentiva
#1 Operator
of Rehabilitation Services(1)
$1.3 billion Revenues(3)
2,237 sites of service
served through 23,058 therapists(4)
Including 104 hospital-based acute rehabilitation units(4)
#8 Operator of Skilled Nursing Facilities (1)
$1.1 billion Revenues(3)
47 Transitional Care
Centers (Sub-Acute facilities (4) licensed as SNFs)
12 Hospital-Based Sub-Acute Units(4)
13 Nursing and Rehabilitation Centers (with (4)
Transitional Care Units)
38 Skilled Nursing
Centers (Traditional SNFs)(4)
(1) Ranking based on revenues.
(2) Ranking from Provider magazine June 20, 2014 issue.
(3) Revenues for the twelve months
ended June 30, 2014 (divisional revenues before intercompany eliminations).
(4) As of June 30, 2014.
(5) Includes Kindred at Home annualized revenues for the three months ended June 30, 2014 and from 2014 current average analyst consensus estimates for Gentiva.
Financial Benefits of the Combination
Pro forma
annual revenues of approximately
$7.1 billion(1)
and Operating Income of
$1.0 billion(1)
Pro Forma Revenue/ Business Mix(2)
31% 35%
18% 16%
Hospital Kindred at Home Rehabilitation Nursing Center
Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the proposed business combination transaction between Kindred Healthcare, Inc. (Kindred) and Gentiva Health Services, Inc.
(Gentiva) (including financing of the proposed transaction and the benefits, results, effects and timing of a transaction), all statements regarding Kindreds (and Kindreds and Gentivas combined) expected future
financial position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management, and statements containing the words
such as anticipate, approximate, believe, plan, estimate, expect, project, could, would, should, will,
intend, may, potential, upside, and other similar expressions. Statements in this communication concerning the business outlook or future economic performance, anticipated profitability, revenues,
expenses, dividends or other financial items, and product or services line growth of Kindred (and the combined businesses of Kindred and Gentiva), together with other statements that are not historical facts, are forward-looking statements that are
estimates reflecting the best judgment of Kindred based upon currently available information.
Such forward-looking statements are inherently uncertain, and
stockholders and other potential investors must recognize that actual results may differ materially from Kindreds expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking
statements are based upon managements current expectations and include known and unknown risks, uncertainties and other factors, many of which Kindred is unable to predict or control, that may cause Kindreds actual results, performance
or plans with respect to Gentiva to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. These statements involve risks, uncertainties and other factors discussed below and detailed
from time to time in Kindreds filings with the Securities and Exchange Commission (the SEC).
Risks and uncertainties related to the proposed
merger include, but are not limited to, the risk that Gentivas stockholders do not approve the merger, potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger, uncertainties
as to the timing of the merger, adverse effects on Kindreds stock price resulting from the announcement or completion of the merger, competitive responses to the announcement or completion of the merger, the risk that healthcare regulatory,
licensure or other approvals and financing required for the consummation of the merger are not obtained or are obtained subject to terms and conditions that are not anticipated, costs and difficulties related to the integration of Gentivas
businesses and operations with Kindreds businesses and operations, the inability to obtain, or delays in obtaining, cost savings and synergies from the merger, uncertainties as to whether the completion of the merger or any transaction will
have the accretive effect on Kindreds earnings or cash flows that it expects, unexpected costs, liabilities, charges or expenses resulting from the merger, litigation relating to the merger, the inability to retain key personnel, and any
changes in general economic and/or industry-specific conditions.
In addition to the factors set forth above, other factors that may affect Kindreds plans,
results or stock price are set forth in Kindreds Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K.
Many of these factors are beyond
Kindreds control. Kindred cautions investors that any forward-looking statements made by Kindred are not guarantees of future performance. Kindred disclaims any obligation to update any such factors or to announce publicly the results of any
revisions to any of the forward-looking statements to reflect future events or developments.
Additional Information
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be
deemed to be solicitation material in respect of the proposed merger between Kindred and Gentiva. In connection with the proposed merger, Kindred intends to file a registration statement on Form S-4, containing a proxy statement/prospectus, with the
SEC. SHAREHOLDERS OF GENTIVA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT/PROSPECTUS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Investors and security holders will be
able to obtain copies of the proxy statement/prospectus as well as other filings containing information about Kindred and Gentiva, without charge, at the SECs website, www.sec.gov. Those documents, when filed, as well as Kindreds other
public filings with the SEC, may be obtained without charge at Kindreds website at www.kindredhealthcare.com.
Participants in Solicitation
Kindred and its directors and executive officers, and Gentiva and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the
holders of Gentiva common stock in respect of the proposed merger. Information about the directors and executive officers of Kindred is set forth in the proxy statement for Kindreds 2014 Annual Meeting of Shareholders, which was filed with the
SEC on April 3, 2014. Information about the directors and executive officers of Gentiva is set forth in the proxy statement for Gentivas 2014 Annual Meeting of Shareholders, which was filed with the SEC on March 25, 2014. Investors may obtain
additional information regarding the interest of such participants by reading the proxy statement/prospectus regarding the proposed merger when it becomes available.
(1) Pro forma revenues and Operating Income (EBITDAR) were computed by combining the midpoint of 2014 guidance for Kindred as provided on August 6, 2014 (a
reconciliation is provided in Kindreds October 9, 2014 press release available on its website at www.kindredhealthcare.com) and 2014 current average analyst consensus estimates for Gentiva. In addition, pro forma EBITDAR includes full run rate
expected cost synergies of $70 million, and estimated annualized rent expense of $41 million based on Gentivas second quarter of 2014. EBITDAR is defined as earnings before interest, income taxes, depreciation, amortization and rent.
(2) Gentiva platform consolidates into Kindred at Home.